

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5222028/ralf-reilmann-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71 papers	4,641 citations	28 h-index	68 g-index
74 ext. papers	5,382 ext. citations	6.8 avg, IF	5.03 L-index

#	Paper	IF	Citations
71	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. <i>Lancet Neurology, The</i> , 2009 , 8, 791-801	24.1	721
70	Huntington disease: natural history, biomarkers and prospects for therapeutics. <i>Nature Reviews Neurology</i> , 2014 , 10, 204-16	15	600
69	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. <i>Lancet Neurology, The</i> , 2013 , 12, 637-49	24.1	557
68	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. <i>Lancet Neurology, The</i> , 2011 , 10, 31-42	24.1	443
67	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. <i>Lancet Neurology, The</i> , 2012 , 11, 42-53	24.1	392
66	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016 , 31, 1272-82		305
65	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2011 , 10, 1049-57	24.1	134
64	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019 , 34, 657-663	7	115
63	Diagnostic criteria for Huntington's disease based on natural history. <i>Movement Disorders</i> , 2014 , 29, 1335-41		110
62	Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. <i>Human Brain Mapping</i> , 2012 , 33, 203-12	5.9	104
61	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. <i>EBioMedicine</i> , 2015 , 2, 1420-9	8.8	91
60	Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. <i>Human Brain Mapping</i> , 2013 , 34, 519-29	5.9	77
59	Coordination of prehensile forces during precision grip in Huntington's disease. <i>Experimental Neurology</i> , 2000 , 163, 136-48	5.7	67
58	The structural correlates of functional deficits in early huntington's disease. <i>Human Brain Mapping</i> , 2013 , 34, 2141-53	5.9	65
57	A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. <i>Movement Disorders</i> , 2015 , 30, 427-31	7	57
56	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. <i>Lancet Neurology, The</i> , 2019 , 18, 165-176	24.1	50
55	Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. <i>Journal of the International Neuropsychological Society</i> , 2011 , 17, 788-95	3.1	49

54	A randomized, controlled trial of a multi-modal exercise intervention in Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 31, 46-52	3.6	49
53	Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures. <i>Movement Disorders</i> , 2011 , 26, 2267-73	7	42
52	Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. <i>Movement Disorders</i> , 2013 , 28, 1030-3	7	38
51	A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. <i>Movement Disorders</i> , 2015 , 30, 393-401	7	38
50	Grasping premanifest Huntington's disease - shaping new endpoints for new trials. <i>Movement Disorders</i> , 2010 , 25, 2858-62	7	37
49	Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. <i>Movement Disorders</i> , 2010 , 25, 2195-202	7	36
48	Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. <i>Movement Disorders</i> , 2014 , 29, 1419-28	7	35
47	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 541-546	2.2	30
46	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019 , 34, 676-681	7	28
45	Motor outcome measures in Huntington disease clinical trials. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017 , 144, 209-225	3	28
44	Huntington's disease: Current and future therapeutic prospects. <i>Movement Disorders</i> , 2018 , 33, 1033-1041	4	28
43	Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study. <i>Human Brain Mapping</i> , 2018 , 39, 1339-1353	5.9	24
42	Association of CAG Repeats With Long-term Progression in Huntington Disease. <i>JAMA Neurology</i> , 2019 , 76, 1375-1385	17.2	22
41	Corpus callosal atrophy in premanifest and early Huntington's disease. <i>Journal of Huntington's Disease</i> , 2013 , 2, 517-26	1.9	21
40	Huntington's disease: objective assessment of posture--a link between motor and functional deficits. <i>Movement Disorders</i> , 2012 , 27, 555-9	7	18
39	Digitomography in Parkinson's disease: a cross-sectional and longitudinal study. <i>PLoS ONE</i> , 2015 , 10, e0123914	3.7	17
38	Behavioral testing of minipigs transgenic for the Huntington gene-A three-year observational study. <i>PLoS ONE</i> , 2017 , 12, e0185970	3.7	17
37	Behavioral phenotyping of minipigs transgenic for the Huntington gene. <i>Journal of Neuroscience Methods</i> , 2016 , 265, 34-45	3	15

36	Neuroimaging of a minipig model of Huntington's disease: Feasibility of volumetric, diffusion-weighted and spectroscopic assessments. <i>Journal of Neuroscience Methods</i> , 2016 , 265, 46-55	3	15
35	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. <i>NeuroImage: Clinical</i> , 2018 , 17, 312-324	5.3	14
34	Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices. <i>Digital Biomarkers</i> , 2019 , 3, 103-115	7.1	13
33	Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study. <i>Gait and Posture</i> , 2018 , 62, 451-457	2.6	11
32	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. <i>JAMA Neurology</i> , 2017 , 74, 1352-1360	17.2	10
31	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. <i>Movement Disorders</i> , 2019 , 34, 584-585	7	8
30	Gait variability as digital biomarker of disease severity in Huntington's disease. <i>Journal of Neurology</i> , 2020 , 267, 1594-1601	5.5	8
29	Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. <i>BMC Neurology</i> , 2015 , 15, 265	3.1	8
28	The Libechov Minipig as a Large Animal Model for Preclinical Research in Huntington's disease - Thoughts and Perspectives. <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2015 , 78/111, 55-60	1.4	8
27	Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. <i>Cerebellum</i> , 2019 , 18, 896-909	4.3	7
26	Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 290-295	2.2	7
25	Huntington's disease: Towards disease modification - Gaps and bridges, facts and opinions. <i>Basal Ganglia</i> , 2012 , 2, 241-248		7
24	Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease. <i>Physical Therapy</i> , 2019 , 99, 1201-1210	3.3	5
23	Activity or Connectivity? Evaluating neurofeedback training in Huntington's disease		4
22	Parkinsonism in Huntington's disease. <i>International Review of Neurobiology</i> , 2019 , 149, 299-306	4.4	4
21	Does arterial hypertension influence the onset of Huntington's disease?. <i>PLoS ONE</i> , 2018 , 13, e0197975	3.7	4
20	Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease. <i>Neurology: Genetics</i> , 2020 , 6, e430	3.8	3
19	Behavioral Assessment of Stress Compensation in Minipigs Transgenic for the Huntington Gene Using Cortisol Levels: A Proof-of-Concept Study. <i>Journal of Huntington's Disease</i> , 2018 , 7, 151-161	1.9	3

18	Huntington's disease: a field on the move. Introduction. <i>Movement Disorders</i> , 2014 , 29, 1333-4	7	3
17	Impaired Isometric Force Matching in Upper and Lower Limbs Revealed by Quantitative Motor Assessments in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2019 , 8, 483-492	1.9	2
16	Minipigs as a Large-Brained Animal Model for Huntington's Disease: From Behavior and Imaging to Gene Therapy. <i>Methods in Molecular Biology</i> , 2018 , 1780, 241-266	1.4	2
15	How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?. <i>Parkinsonism and Related Disorders</i> , 2020 , 81, 213-218	3.6	2
14	Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 208-214	2.2	2
13	FDG PET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease [A 15 Months Follow-up Study]. <i>Journal of Huntington's Disease</i> , 2015 , 4, 37-47	1.9	2
12	How to evaluate effects of occupational therapy - lessons learned from an exploratory randomized controlled trial. <i>Parkinsonism and Related Disorders</i> , 2019 , 67, 42-47	3.6	1
11	Immediate effects of treadmill walking in individuals with Lewy body dementia and Huntington's disease. <i>Gait and Posture</i> , 2021 , 86, 186-191	2.6	1
10	Vocalisation as a Viable Assessment for Phenotyping Minipigs Transgenic for the Huntington Gene?. <i>Journal of Huntington's Disease</i> , 2018 , 7, 269-278	1.9	1
9	Cognitive decline in Huntington's disease in the Digitalized Arithmetic Task (DAT). <i>PLoS ONE</i> , 2021 , 16, e0253064	3.7	1
8	Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. <i>BMC Neurology</i> , 2019 , 19, 118	3.1	0
7	A Feasibility Study of Quantitative Motor Assessments in Children Using the Q-Motor Suite. <i>Journal of Huntington's Disease</i> , 2019 , 8, 333-338	1.9	0
6	E2 Progression of motor subtypes in huntington's disease: a six-year follow-up study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A45.2-A45	5.5	
5	An important step towards translation of stem cell therapies in clinical applications for neurodegenerative diseases and beyond?. <i>Movement Disorders</i> , 2012 , 27, 1355-6	7	
4	Does chromatin modulation provide the first wet biomarker for Huntington's disease?. <i>Movement Disorders</i> , 2012 , 27, 473	7	
3	Progression of premanifest and early Huntington's disease detectable after 1 yearDoes TRACK-HD open the door to disease-modifying trials in HD and beyond?. <i>Movement Disorders</i> , 2011 , 26, 605	7	
2	Objectively characterizing Huntington's disease using a novel upper limb dexterity test. <i>Journal of Neurology</i> , 2021 , 268, 2550-2559	5.5	
1	On the rise: Quantitative measures in Huntington's disease. <i>Movement Disorders</i> , 2018 , 33, 1370-1371	7	

